| Patent Number |
Title Of Patent |
Date Issued |
| 6322964 |
Synthetic HIV-2 gag and env oligopeptides reactive with HIV-2 specific antibodies |
November 27, 2001 |
| Peptide sequences are disclosed which immunologically mimic proteins encoded by the env and gag regions of LAV-2, a retrovirus associated with AIDS. The peptide can be used in various specific binding assays to detect the presence of antibodies to LAV-2 in individuals previously exposed |
| 6130314 |
Synthetic antigen for the detection of AIDS-related disease |
October 10, 2000 |
| Novel peptides are provided having substantially the same sequence as immunologically significant fragments of AIDS-related viruses. The polypeptides can be used as reagents in the determination of exposure of a human host to the virus. Of particular interest is the use of polypeptides |
| 5716829 |
Diagnostic test for Pseudomonas aeruginosa infections |
February 10, 1998 |
| Methods and reagents are provided for a novel immunodiagnostic test for the presence of P. aeruginosa in a biological sample. Monoclonal antibodies are employed which bind to an outer membrane protein antigen, which may be exposed by a solubilizing reagent. The antibody binds substantial |
| 5514542 |
Methods for propagating retrovirus for use in antibody assays |
May 7, 1996 |
| Cell lines which lack human class II histocompatibility antigens are disclosed. The cell lines may be utilized within a method for propagating microorganisms, such as viruses, for determining the presence and/or amount of antibody to a microorganism in a biological fluid, and within a |
| 5459043 |
Hybridoma CT43 producing a monoclonal antibody to a novel mucin epitope which correlates with th |
October 17, 1995 |
| The present invention relates to a novel monoclonal antibody reactive with human colorectal mucin antigen. More particularly, the antibody of the invention is a murine monoclonal antibody, CT43, reactive with a novel antigenic determinant on much antigen highly correlated with human |
| 5439792 |
Cysteine thiol-protected peptides for use in immunoassays |
August 8, 1995 |
| Peptides immunoreactive with antibodies to native proteins, and which have at least two cysteine residues that contribute to mimicking an epitope of the protein, are prepared with the cysteine thiol groups protected. When deprotected, the peptides have enhanced immunoreactivity. The pept |
| 5369010 |
Monoclonal antibody to polymorphic HLA determinant -B27 |
November 29, 1994 |
| Novel cell lines, receptors and monoclonal antibodies prepared therefrom that are specific for the human HLA-B27 antigen are provided. The monoclonal antibodies are useful in diagnosis and therapy, particularly with respect to certain rheumatoid disorders. |
| 5206178 |
Membrane affinity concentration immunoassay |
April 27, 1993 |
| Methods for determining the presence and/or concentration of an analyte in a biological fluid sample are disclosed. The methods generally include admixing in solution certain polymer/reactant and reporter/reactant conjugates along with the biological fluid sample suspected of containing |
| 5206136 |
Rapid membrane affinity concentration assays |
April 27, 1993 |
| Rapid assays for analytes of interest in a fluid sample utilize a first conjugate of a labelled reactant that specifically binds to the analyte, and a second conjugate that binds to the analyte coupled to a polymer that has an affinity for a selected solid phase. The reaction components |
| 5196308 |
Methods for identifying the DQw3.2 allele associated with increased risk of insulin-dependent di |
March 23, 1993 |
| Methods for identifying individuals at increased risk of diabetes are disclosed. The methods disclosed utilize the discovery of the DQw3.2 variant, which identifies a specific allelic polymorphism at a sinle gene locus. One preferred method utilizes a labeled probe to detect the DQw3.2 |
| 5175098 |
Expression and diagnostic use of gag encoded peptides which are immunologically reactive with an |
December 29, 1992 |
| Immunologically reactive gag proteins of LAV are expresesed in bacterial cells. The gag proteins are encoded by a recombinant plasmid containing procaryotic transcriptional and translational signals for expression, followed downstream by a DNA sequence comprising a portion of the gag |
| 5175097 |
Expression and diagnostic use of GAG-1 encoded peptides which are immunologically reactive with |
December 29, 1992 |
| Immunologically reactive gag proteins of LAV/HTLV-III are expressed in bacterial cells. The gag proteins are encoded by a recombinant plasmid containing procaryotic transcriptional and translational signals for expression, followed downstream by a DNA sequence comprising pGAG-1. Pref |
| 5104790 |
Monoclonal antibodies to specific antigenic regions of the human immunodeficiency virus and meth |
April 14, 1992 |
| Monoclonal antibodies capable of binding antigenic determinants within regions of the core proteins of the Human Immunodeficiency Virus and immortalized cell lines producing those monoclonal antibodies are provided. The monoclonal antibodies find use in a variety of ways, including H |
| 5087557 |
Human monoclonal antibody to lymphadenopathy-associated virus |
February 11, 1992 |
| Human monoclonal antibodies capable of specifically reacting with an antigenic determinant of LAV/HTLV-III and cell lines producing those monoclonal antibodies are disclosed. The human monoclonal antibodies may be utilized in a method for determining the presence of LAV/HTLV-III in b |
| 5075211 |
Synthetic antigen for the detection of AIDS-related disease |
December 24, 1991 |
| Novel peptides are provided having substantially the same sequence as immunologically significant fragments of AIDS-related viruses. The polypeptides can be used as reagents in the determination of exposure of a human host to the virus. Of particular interest is the use of polypeptides |
| 5068178 |
Method of enhancing direct immunofluorescence staining of cells |
November 26, 1991 |
| A method of identifying and enumerating specific cell types in a heterogeneous population of cells by enhancing the specific staining of desired cells, comprising contacting a sample from the heterogeneous population of cells with a labeled primary antibody which recognizes and binds |
| 5002889 |
Reaction well shape for a microwell tray |
March 26, 1991 |
| A microwell for enzyme-linked immunosorbent assays has a concavely curved, circumferential sidewall, a flat optical bottom and a top lip, including smooth transitions between the top lip, concave sidewall and flat bottom. This shape minimizes the tendency of fluid to cling to the well fo |
| 4970070 |
Protective monoclonal antibody compositions for infections due to group B streptococcus |
November 13, 1990 |
| Immortalized cell lines have been produced that secrete human monoclonal antibodies capable of binding to bacterial species which are a major cause of neonatal sepsis and meningitis. These antibodies have been found to be protective against lethal challenges of these bacteria, which incl |
| 4851333 |
Method and composition for the detection and diagnosis of Legionella pneumophila |
July 25, 1989 |
| Method and compositions including monoclonal antibodies to a serogroup-common antigen are provided for the detection and diagnosis of Legionella pneumophila. The monoclonal antibodies recognize a proteinaceous antigen of molecular weight 28,000-29,000 Daltons which is detected in at |
| 4843010 |
Polymerization-induced separation immunoassays |
June 27, 1989 |
| Immunoassay methods and compositions are disclosed for the detection of analytes in fluid samples. The disclosure provides conjugates of analytes or reactants with polymerizable organic monomers. Specific binding reactions between reactants are detected by means of resporter/reactant |
| 4834976 |
Monoclonal antibodies to pseudomonas aeruginosa flagella |
May 30, 1989 |
| Cell lines have been produced that secrete monoclonal antibodies capable of binding to the flagellar proteins of selected Pseudomonas aeruginosa strains. Some of these antibodies have been found to be protective against lethal challenges of P. aeruginosa. Pharmaceutical compositions cont |
| 4784941 |
Expression and diagnostic use of pENV-3 encoded peptides which are immunologically reactive with |
November 15, 1988 |
| A method of expressing peptides which are immunologically reactive with antibodies to LAV is disclosed. The peptides are produced by bacterial host cells transformed with a recombinant plasmid which includes appropriate procaryotic transcriptional and translational signals for expres |
| 4780409 |
Thermally induced phase separation immunoassay |
October 25, 1988 |
| An immunoassay in which a thermally induced phase separation is used to effect the separation of specifically bound reactants from free reactants is disclosed. A first reactant is conjugated to a temperature-sensitive polymer to form a polymer/reactant conjugate, and a second reactant is |
| 4752638 |
Synthesis and use of polymers containing integral binding-pair members |
June 21, 1988 |
| Conjugate monomers, polymers, and methods for the de novo synthesis of the polymers are provided. Conjugate organic monomers contain binding-pair members which upon polymerization become integrally associated with the resultant polymer. Specifically, antigens, antibodies, receptors, and |
| 4749647 |
Polymerization-induced separation assay using recognition pairs |
June 7, 1988 |
| Methods and compounds are disclosed for determining the presence, amount of, or association between substances of interest in samples suspected of containing same. The methods are based on the polymerization-induced separation of specifically-bound, reporter-labeled recognition reactants |
| 4711840 |
Polymerization-induced separation immunoassays |
December 8, 1987 |
| Immunoassay methods and compositions are disclosed for the detection of one or more analytes in fluid samples. The disclosure provides conjugates of analytes or reactants with polymerizable organic monomers. Specific binding reactions between reactants are detected by means of report |
| 4677061 |
T-cell lymphocyte subset monitoring of immunologic disease |
June 30, 1987 |
| Methods and compositions are provided for determining a change in status of a multiple sclerosis victim. Particularly, the ratio of helper or suppressor T cell subsets having specific surface markers associated with proliferation is determined, where a particular ratio value is associate |
| 4629783 |
Synthetic antigen for the detection of AIDS-related disease |
December 16, 1986 |
| Novel peptides are provided having substantially the same sequence as immunologically significant fragments of AIDS-related viruses. The polypeptides can be used as reagents in the determination of exposure of a human host to the virus. Of particular interest is the use of polypeptides |
| 4609707 |
Synthesis of polymers containing integral antibodies |
September 2, 1986 |
| A method is disclosed for the de novo synthesis of antibody-containing polymers and the preparation of a class of polymerizable compounds used in the synthesis of such antibody-containing polymers. Antibody-containing polymers formed from monomer/antibody conjugates and nonderivatized |
| 4511478 |
Polymerizable compounds and methods for preparing synthetic polymers that integrally contain pol |
April 16, 1985 |
| A method is disclosed for the de novo synthesis of polypeptide-containing polymers. This disclosure also includes a description of, and a method for the preparation of, a class of polymerizable compounds used in the synthesis of polypeptide-containing polymers. These polymerizable co |
| 4464465 |
Cell-driven viral transfer in eukaryotes |
August 7, 1984 |
| Novel method, cells and compositions are provided involving transforming B-lymphocytes to provide immortalization for continuous production of monoclonal antibodies to a predetermined ligand. T-cell free B-lymphocytes are combined with an Epstein-Barr virus transformed cell sensitive to |
